ArticleAnnals of surgical oncology2026
Beyond Pathological Complete Response: Long-term Outcomes in Esophageal and Esophagogastric Junction Adenocarcinoma After Multimodal Therapy-A Systematic Review and Individual Patient-Data Meta-Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Beyond Pathologic Complete Response-Why Treatment Strategy Matters.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemotherapy (nCT) for esophageal and esophagogastric junction (EGJ) adenocarcinoma is associated with better survival but worse pathological complete response (pCR) rate as compared with neoadjuvant chemoradiotherapy (nCRT). The aim of the present study is to compare long-term outcomes in patients with esophageal or EGJ adenocarcinoma and pCR after nCT or nCRT. PATIENTS AND
methodsA systematic review of the literature in PubMed, Embase and web sources was performed up to November 2025. Studies comparing nCT and nCRT in patients with esophageal or EGJ adenocarcinoma and pCR were identified. An individual patient-data (IPD) meta-analysis was performed for overall survival (OS) and disease-free survival (DFS).
resultsOverall, 1454 patients from six different studies were included (374 in nCT group and 1080 in nCRT group). 1-, 3-, and 5-year OS was superior in the nCT group as compared with nCRT group, being 95.4% versus 87.8%, 81.5% versus 64.8% and 73.8% versus 56%, respectively (p < 0.001). Analogously, superior DFS was observed for the nCT group at one, three and 5 years (p < 0.001). In the one-stage meta-analysis nCT was associated with decreased risk of death (HR = 0.49, p < 0.001) and recurrence (HR = 0.24, p <0.001).
conclusionsThe present study showed better long-term outcomes in patients with pCR after nCT when compared with nCRT, highlighting the better systemic disease control offered by the first. This consideration suggests that pCR cannot be considered as a prognostic surrogate per se but the integration of this concept with the type of preoperative strategy is crucial.
Indexed as
Identifiers
42509408What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.